4.7 Review

Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges

Journal

Publisher

MDPI
DOI: 10.3390/ijms241411780

Keywords

aptamer; neuroinflammation; neurodegeneration; alzheimer's disease; parkinson's disease; microglia

Ask authors/readers for more resources

Neuroinflammation is a precursor to neurodegenerative diseases, and targeting it with aptamers offers potential diagnostic and therapeutic applications. This review summarizes the use of aptamers for diagnosing and treating inflammatory biomolecules and cells associated with neurodegenerative diseases. It also discusses the potential of short nucleotides for targeted brain delivery and the challenges of using aptamers as therapeutic agents. Overall, this review assesses the potential of aptamers as a pioneering approach for CNS target delivery and the treatment of neuroinflammation and neurodegenerative diseases.
Neuroinflammation is the precursor for several neurodegenerative diseases (NDDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). Targeting neuroinflammation has emerged as a promising strategy to address a wide range of CNS pathologies. These NDDs still present significant challenges in terms of limited and ineffective diagnosis and treatment options, driving the need to explore innovative and novel therapeutic alternatives. Aptamers are single-stranded nucleic acids that offer the potential for addressing these challenges through diagnostic and therapeutic applications. In this review, we summarize diagnostic and therapeutic aptamers for inflammatory biomolecules, as well as the inflammatory cells in NDDs. We also discussed the potential of short nucleotides for Aptamer-Based Targeted Brain Delivery through their unique features and modifications, as well as their ability to penetrate the blood-brain barrier. Moreover, the unprecedented opportunities and substantial challenges of using aptamers as therapeutic agents, such as drug efficacy, safety considerations, and pharmacokinetics, are also discussed. Taken together, this review assesses the potential of aptamers as a pioneering approach for target delivery to the CNS and the treatment of neuroinflammation and NDDs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available